“…It is an adaptive compensatory and therefore beneficial response aimed at maintaining energy balance and minimizing protein wasting in diseased states [5]. However, altered thyroid hormone metabolism, characterized by low circulating T3 levels, has been described in patients with cardiovascular disease, pulmonary disorders, chronic kidney disease and brain tumor [6,7,8,9], suggested that this alteration is less benign than previously thought [10]. And recent studies showed that low-T3 during the acute phase of AIS may be a predictor of poor clinical and functional outcomes [11,12].…”